Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 3:38 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 439 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Excretion Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

An Open-Label Phase 1 Study in Healthy Male Subjects to Investigate the Absorption, Metabolism and Excretion of [14C]-EP262 Following Single-Dose Oral Administration

NCT06645704
View directory record Official record
Conditions
Healthy Participants
Interventions
EP262
Drug
Lead sponsor
Escient Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 24, 2025 · Synced Oct 19, 2026, 3:38 AM EDT
Completed Phase 3 Interventional Results available

Plaque Regression and Progenitor Cell Mobilization With Intensive Lipid Elimination Regimen (PREMIER), Phase II

NCT02347098
View directory record Official record
Conditions
Acute Coronary Artery Syndrome
Interventions
intensive LDL-lowering therapy, standard statin monotherapy
Device · Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
31 Years and older
Enrollment
270 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
4
States / cities
Denver, Colorado • Oklahoma City, Oklahoma • Nashville, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2019 · Synced Oct 19, 2026, 3:38 AM EDT
Completed Phase 3 Interventional Results available

Treatment of Encopresis in Children With Autism Spectrum Disorders

NCT03197922
View directory record Official record
Conditions
Encopresis, Autism Spectrum Disorder
Interventions
MIE Treatment, Glycerin Suppository, Treatment as Usual (TAU)
Behavioral · Drug · Combination Product
Lead sponsor
Emory University
Other
Eligibility
5 Years to 12 Years
Enrollment
117 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 31, 2024 · Synced Oct 19, 2026, 3:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Mass Balance Study of KBP-5074 in Healthy Male Subjects

NCT04634812
View directory record Official record
Conditions
Healthy
Interventions
KBP-5074
Drug
Lead sponsor
KBP Biosciences
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
7 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 19, 2026, 3:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Open-label Study of the Absorption, Metabolism, and Excretion of [14C]-Simufilam Following a Single Oral Dose in Healthy Male Subjects

NCT06195319
View directory record Official record
Conditions
Absorption, Metabolism, Excretion
Interventions
Simufilam
Drug
Lead sponsor
Cassava Sciences, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Mar 20, 2025 · Synced Oct 19, 2026, 3:38 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Study to Learn How Different Amounts of the Study Medicine Called PF-08103402 Are Tolerated and Act in the Body in Healthy Adults or Adults With Mild To-moderate Asthma

NCT07660731
View directory record Official record
Conditions
Healthy Volunteer Study, Healthy Adults, Healthy Participants, Asthma
Interventions
PF-08103402, Placebo, Midazolam
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 65 Years
Enrollment
133 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Oct 13, 2026 · Synced Oct 19, 2026, 3:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study of the Absorption, Metabolism, and Excretion of [14C] PBI-200

NCT05238337
View directory record Official record
Conditions
Absorption, Metabolism and Excretion in Healthy Volunteers
Interventions
[14C]-PBI-200
Drug
Lead sponsor
Pyramid Biosciences
Industry
Eligibility
18 Years to 65 Years · Male only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Aug 30, 2022 · Synced Oct 19, 2026, 3:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of the Absorption, Metabolism, and Excretion of Tucatinib in Healthy Participants

NCT03758339
View directory record Official record
Conditions
Healthy
Interventions
tucatinib
Drug
Lead sponsor
Cascadian Therapeutics Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Nov 29, 2018 · Synced Oct 19, 2026, 3:38 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

False Safety Behavior Elimination Therapy: A Randomized Study of a Brief Individual Transdiagnostic Treatment for Anxiety Disorders

NCT02082561
View directory record Official record
Conditions
Panic Disorder, Generalized Anxiety Disorder, Social Anxiety Disorder
Interventions
Transdiagnostic Treatment (F-SET)
Behavioral
Lead sponsor
Florida State University
Other
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2012
U.S. locations
1
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Mar 10, 2014 · Synced Oct 19, 2026, 3:38 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Addition of Phytosterols to a Low Phytosterol Diet

NCT00860054
View directory record Official record
Conditions
Hypercholesterolemia, Coronary Heart Disease
Interventions
Different amount of phytosterols are added into diets
Dietary Supplement
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 80 Years
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 19, 2012 · Synced Oct 19, 2026, 3:38 AM EDT
Completed Phase 1 Interventional Results available

Pembrolizumab and Concurrent Chemoradiotherapy or Radiation Therapy in Treating Patients With Small Cell Lung Cancer

NCT02402920
View directory record Official record
Conditions
Extensive Stage Small Cell Lung Carcinoma, Limited Stage Small Cell Lung Carcinoma, Neuroendocrine Neoplasm
Interventions
Carboplatin, Cisplatin, Etoposide, Laboratory Biomarker Analysis, Pembrolizumab, Radiation Therapy
Drug · Other · Biological + 1 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
83 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2026
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 10, 2026 · Synced Oct 19, 2026, 3:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase 1 Study to Evaluate ASN002 Absorption, Metabolism, and Excretion of [14C] Following a Single Oral Dose in Healthy Male Subjects

NCT03641573
View directory record Official record
Conditions
Healthy Volunteer
Interventions
[14C] ASN002
Drug
Lead sponsor
Asana BioSciences
Industry
Eligibility
20 Years to 60 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 28, 2020 · Synced Oct 19, 2026, 3:38 AM EDT
Completed Not applicable Interventional Results available

PureWick™ France and U.S. At-Home Pilot Study

NCT05710718
View directory record Official record
Conditions
Nocturnal Enuresis
Interventions
PureWick™ System, Hollister® Female Urinary Pouch External Collection Device
Device
Lead sponsor
C. R. Bard
Industry
Eligibility
18 Years and older · Female only
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2024
U.S. locations
2
States / cities
Dunwoody, Georgia • New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 16, 2025 · Synced Oct 19, 2026, 3:38 AM EDT
Active, not recruiting Phase 4 Interventional

Kebele Elimination of Trachoma for Ocular Health

NCT03335072
View directory record Official record
Conditions
Trachoma
Interventions
Azithromycin
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
Not listed
Enrollment
320,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Oct 23, 2025 · Synced Oct 19, 2026, 3:38 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Exparel PK and Breast Milk Excretion

NCT03526419
View directory record Official record
Conditions
Milk Expression, Breast
Interventions
Bupivacaine liposome
Drug
Lead sponsor
University of Minnesota
Other
Eligibility
18 Years and older · Female only
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 25, 2019 · Synced Oct 19, 2026, 3:38 AM EDT
Terminated Phase 4 Interventional Results available

Dysfunctional Voiding and Lower Urinary Tract Symptoms With Baclofen

NCT01003249
View directory record Official record
Conditions
Overactive Bladder, Constipation, Lower Urinary Tract Symptoms
Interventions
Baclofen, Placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 64 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 14, 2018 · Synced Oct 19, 2026, 3:38 AM EDT
Terminated Phase 2 Interventional Results available

Safety and Efficacy of Chlorthalidone in Type 1 Diabetes

NCT03325114
View directory record Official record
Conditions
Type 1 Diabetes Mellitus, Hypercalciuria
Interventions
Chlorthalidone
Drug
Lead sponsor
University of Rochester
Other
Eligibility
12 Years to 21 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Rochester, New York
Source: ClinicalTrials.gov public record
Updated Jan 5, 2021 · Synced Oct 19, 2026, 3:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

RDEA3170 AME Study

NCT01910506
View directory record Official record
Conditions
Healthy
Interventions
RDEA3170 10 mg
Drug
Lead sponsor
Ardea Biosciences, Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 9, 2014 · Synced Oct 19, 2026, 3:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate How the Body Processes 14C-VX-993 After a Single Oral Dose

NCT06886269
View directory record Official record
Conditions
Pain
Interventions
14C-VX-993
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jun 18, 2025 · Synced Oct 19, 2026, 3:38 AM EDT
Completed No phase listed Observational

Propagation ANalysis for Arrhythmogenic Conduction Elimination to Prevent Atrial Flutter and Fibrillation (PANACEA-AF)

NCT03737838
View directory record Official record
Conditions
Atrial Fibrillation
Interventions
Atrial fibrillation ablation
Device
Lead sponsor
University of Chicago
Other
Eligibility
18 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 7, 2024 · Synced Oct 19, 2026, 3:38 AM EDT
Terminated Phase 3 Interventional

ARD-101 for Treatment of PWS: The Hunger Elimination or Reduction Objective Trial

NCT06828861
View directory record Official record
Conditions
Hyperphagia, Prader-Willi Syndrome
Interventions
Placebo, ARD-101
Drug
Lead sponsor
Aardvark Therapeutics, Inc.
Industry
Eligibility
7 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
17
States / cities
Birmingham, Alabama • Encinitas, California • Orange, California + 14 more
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 19, 2026, 3:38 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Identification to Elimination in HCV-Infected Individuals

NCT03195205
View directory record Official record
Conditions
Hepatitis C
Interventions
OraQuick HCV Rapid Antibody Test
Diagnostic Test
Lead sponsor
TruCare Internal Medicine & Infectious Disease
Other
Eligibility
18 Years and older
Enrollment
3,051 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2020
U.S. locations
1
States / cities
DuBois, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 2, 2020 · Synced Oct 19, 2026, 3:38 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Acid-Base Compensation in Chronic Kidney Disease

NCT02427594
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Sodium bicarbonate, Controlled diet
Drug · Other
Lead sponsor
Duke University
Other
Eligibility
22 Years and older
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 30, 2017 · Synced Oct 19, 2026, 3:38 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Absorption, Metabolism, and Excretion of (-)-[2-14C]Epicatechin in Humans

NCT01969994
View directory record Official record
Conditions
ADME
Interventions
Controlled dietary background, (-)-[2-14C]epicatechin intake
Other
Lead sponsor
The Institutes for Pharmaceutical Discovery, LLC
Industry
Eligibility
18 Years to 50 Years · Male only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Oct 25, 2013 · Synced Oct 19, 2026, 3:38 AM EDT